ITM, Helmholtz Munich and University Hospital Münster Announce First Patient Dosed in Phase I Investigator-Initiated Glioblastoma Trial
April 23, 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
A Novel Therapeutic Approach to Treatment using ITM-31 Garching/Munich, Munich and Münster, April 23, 2024 – The Departments of Neurosurgery and Nuclear Medicine at the University...
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
March 07, 2024 07:30 ET
|
Mustang Bio, Inc.
MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively ~70% improvement in...
Ivy Brain Tumor Center Announces Promising Data for Niraparib in Phase 0/2 Glioblastoma Clinical Trial
November 17, 2023 08:00 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute announces promising results from a Phase 0/2 trial of niraparib in patients with newly...
invIOs and Dana-Farber Cancer Institute start collaboration to study novel small molecule INV501 for treatment of glioblastoma
November 09, 2023 05:30 ET
|
invIOs GmbH
Preclinical study will be conducted by Dr. David Reardon’s research groupImmune-activating small molecule INV501 will be tested as treatment for aggressive brain cancer VIENNA, Austria and BOSTON,...
Ivy Center Announces First Patient Treated in Targeted Phase 0/1 Clinical Trial for High-Grade Glioma
November 06, 2023 10:00 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute announced the first patient has been treated in a novel Phase 0/1 clinical trial of...
Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma
October 26, 2023 09:00 ET
|
Mustang Bio, Inc.
MB‐101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) are separately well tolerated in patients with recurrent GBM in ongoing Phase 1 clinical trials; preclinical data...
Ivy Brain Tumor Center Announces Results of Phase 0/1 Study in Recurrent Glioblastoma Patients at the European Society for Medical Oncology (ESMO) 2023 Congress
October 18, 2023 02:00 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, Oct. 18, 2023 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute announced initial results from a Phase 0/1 clinical trial of the Ataxia telangiectasia...
Ivy Brain Tumor Center Opens Novel Clinical Trial to Test Direct-to-Tumor Drug Delivery Method
July 18, 2023 09:30 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, July 18, 2023 (GLOBE NEWSWIRE) -- In an effort to discover new treatments for brain tumors, such as glioblastoma, the Ivy Brain Tumor Center at Barrow Neurological Institute, announced...
Results of Annual General Meeting and General Meeting
June 14, 2023 08:30 ET
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Results of Annual General Meeting and General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a...
Ivy Brain Tumor Center Announces Interim Results of Two Clinical Trials Targeting High-Grade Glioma
June 02, 2023 15:50 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, June 02, 2023 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, the nation’s largest early-phase drug development program dedicated to brain cancer, is...